Please login to the form below

Not currently logged in

Excellence in Managing Established Products

Sponsored by

Back to Results


‘No Compromise For Her’ Creative Educational Campaign

by UCB Pharma S.A. with support from Carling Communications London

Summary of work

For women of child-bearing age (WoCBA) with rheumatological conditions, the joy of becoming pregnant is often accompanied by fears that their disease will worsen during pregnancy or that their disease or treatment will harm, or be passed on to, their baby.

Following a directive from an international European League Against Rheumatism (EULAR) Task Force calling for the development and dissemination of rheumatic drug exposure data to help to improve the management of pregnant and lactating patients with rheumatic diseases, UCB Pharma S.A. embarked upon a WoCBA-dedicated, evidence-based, creative educational campaign to inform healthcare professionals that, if clinically needed, CIMZIA could continue to be used pre-partum and post-partum.

The campaign centred around a unique ‘No Compromise For Her’ creative rebranding, ultimately showcased at the EULAR 2018 UCB booth, which featured a number of striking and innovative WoCBA-focused activities.

Three months after the campaign launch, awareness of CIMZIA’s pregnancy and lactation data increased significantly from 50% to 78% across the EU5 countries, and the proportion of rheumatologists who believed that a woman falling pregnant should discontinue her anti-TNF, decreased markedly from 64% to 37%.

Judges' comments

‘No Compromise for Her’ was as all about change. It was extremely well set out and shared the decision-making, including from a patient perspective. It targeted the patient profile, aligned to an unmet need was solid from end to end, with great outcomes.

Highly commended

Octasa Sales and Marketing Campaign - by Tillotts Pharma UK


You Go Beyond - by Align Technology with support from Page & Page We all go beyond

The SPIRIVA® RESPIMAT® Success Story - by Boehringer Ingelheim with support from Aptus Health International

Striving for Better Patient Outcomes in Psoriasis with Cosentyx (secukinumab) - by Novartis UK with support from 90TEN

Key dates

Entry deadline 26 August 2022
Extended entry deadline 2 September 2022*
*additional fee applies
Judging Day 6 October 2022
Company/Team of the Year Interviews 21 October 2022
PMEA Event 23 November 2022